The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Lenalidomide downregulates the cell survival factor, interferon regulatory factor‐4, providing a potential mechanistic link for predicting response
Open accessAbstract
Summary: Overexpression of the transcription factor interferon regulatory factor‐4 (IRF4), which is common in multiple myeloma (MM), is associated with poor prognosis. Patients with higher IRF4 expression have significantly poorer overall survival than those with low IRF4 expression. Lenalidomide is an IMiD® immunomodulatory compound that has both tumouricidal and immunomodulatory activity in MM. This study showed that lenalidomide downregulated IRF4 levels in MM cell lines and bone marrow samples within 8 h of drug exposure. This was associated with a decrease in MYC levels, as well as an initial G1 cell cycle arrest, decreased cell proliferation, and cell death by day 5 of treatment. In eight MM cell lines, high IRF4 levels correlated with increased lenalidomide sensitivity. The clinical significance of this observation was investigated in 154 patients with MM. Among MM patients with high levels of IRF4 expression, treatment with lenalidomide led to a significantly longer overall survival than other therapies in a retrospective analysis. These data confirm the central role of IRF4 in MM pathogenesis; indicate that this is an important mechanism by which lenalidomide exerts its antitumour effects; and may provide a mechanistic biomarker to predict response to lenalidomide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Rajkumar, S. V., Jacobus, S., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. E., Abonour, R., Siegel, D. S., Katz, M., & Greipp, P. R. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70284-0 · Cited by 933
Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
IRF4 addiction in multiple myeloma
Shaffer, A. L., Emre, N. C. T., Lamy, L., Ngo, V. N., Wright, G., Xiao, W., Powell, J., Dave, S., Yu, X., Zhao, H., et al. (2008) · Nature · doi:10.1038/nature07064 · Cited by 730
Requirement for the Transcription Factor LSIRF/IRF4 for Mature B and T Lymphocyte Function
Mittrücker, H.-W., Matsuyama, T., Grossman, A., Kündig, T. M., Potter, J., Shahinian, A., Wakeham, A., Patterson, B., Ohashi, P. S., & Mak, T. W. (1997) · Science · doi:10.1126/science.275.5299.540 · Cited by 583
Richardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015909 · Cited by 523
Research works printed but not linked: 38
- 10.1182/blood-2007-10-117838 · DOI
- 10.1053/j.seminhematol.2005.10.001 · DOI · Paper page
- 10.1016/j.ccr.2007.07.004 · DOI · Paper page
- 10.3109/10428191003721342 · DOI
- 10.1182/blood-2002-01-0104 · DOI
- 10.1016/j.immuni.2008.10.011 · DOI · Paper page
- 10.1093/jncimonographs/lgn011 · DOI
- 10.1038/leu.2009.147 · DOI · Paper page
- Dimopoulos M.A., 2011, Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement, Leukemia, 3, 1
- 10.1038/sj.leu.2404284 · DOI · Paper page
- 10.1158/0008-5472.CAN-08-4898 · DOI · Paper page
- 10.1172/JCI24096 · DOI
- 10.1038/leu.2008.320 · DOI · Paper page
- 10.1517/14656560802627903 · DOI
- 10.1016/j.leukres.2006.01.010 · DOI
- 10.2174/156800910791054239 · DOI · Paper page
- 10.1084/jem.191.8.1281 · DOI · Paper page
- 10.1097/PAS.0b013e3181bb9a18 · DOI
- 10.1084/jem.190.12.1837 · DOI
- 10.1038/sj.leu.2404895 · DOI
- 10.1182/blood.V96.9.2943 · DOI · Paper page
- 10.1182/blood-2010-04-278432 · DOI · Paper page
- 10.1038/ng1097-226 · DOI · Paper page
- 10.1111/j.1349-7006.2002.tb01307.x · DOI
- Li S., 2009, Lenalidomide shuts down the translational machinery in multiple myeloma cells resulting in down‐regulation of critical transcription factors such as C/EBPβ and IRF4 [abstract], Blood, 114
- 10.3324/haematol.10682 · doi:10.3324/haematol.10682
- 10.1128/MCB.01946-07 · DOI
- 10.1084/jem.20011128 · DOI · Paper page
- 10.1053/j.seminhematol.2005.10.004 · DOI
- 10.1182/blood-2008-12-196238 · DOI · Paper page
- 10.1158/1078-0432.CCR-08-1845 · DOI · Paper page
- 10.1111/j.0303-6987.2005.00298.x · doi:10.1111/j.0303-6987.2005.00298.x
- 10.1038/sj.leu.2401696 · DOI · Paper page
- 10.1038/sj.leu.2403833 · DOI
- 10.1182/blood.V88.6.2219.bloodjournal8862219 · DOI
- 10.1080/10428190802005191 · DOI
- 10.1158/0008-5472.CAN-06-2317 · DOI · Paper page
- 10.1182/blood-2006-07-038703 · DOI · Paper page
Cited by
Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013) · Nature Methods · doi:10.1038/nmeth.2688 · Cited by 6,422
Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814
Self-citationCereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Van Wier, S., Chang, X.-B., Bjorklund, C. C., Fonseca, R., Bergsagel, P. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-356063 · Cited by 607
Chamberlain, P. P., Lopez-Girona, A., Miller, K., Carmel, G., Pagarigan, B., Chie-Leon, B., Rychak, E., Corral, L. G., Ren, Y. J., Wang, M., et al. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2874 · Cited by 531
Self-citationExploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
Yang, Y., Shaffer, A. L., Emre, N. C. T., Ceribelli, M., Zhang, M., Wright, G., Xiao, W., Powell, J., Platig, J., Kohlhammer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.024 · Cited by 521
Metadata
- Authors
- Lopez‐Girona, A., Heintel, D., Zhang, L., Mendy, D., Gaidarova, S., Brady, H., Bartlett, J. B., Schafer, P. H., Schreder, M., Bolomsky, A., Hilgarth, B., Zojer, N., Gisslinger, H., Ludwig, H., Daniel, T., Jäger, U., & Chopra, R.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2011-06-24
- Volume
- 154
- Issue
- 3
- Pages
- 325-336
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W1537559901
- Cited by
- 181
- References
- 7
- FWCI
- 9.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lenalidomide downregulates the cell survival factor, interferon regulatory factor‐4, providing a potential mechanistic link for predicting response. https://app.cochat.ai/papers/10.1111/j.1365-2141.2011.08689.x
- The paper
- Lopez‐Girona, A., Heintel, D., Zhang, L., Mendy, D., Gaidarova, S., Brady, H., Bartlett, J. B., Schafer, P. H., Schreder, M., Bolomsky, A., Hilgarth, B., Zojer, N., Gisslinger, H., Ludwig, H., Daniel, T., Jäger, U., & Chopra, R. (2011). Lenalidomide downregulates the cell survival factor, interferon regulatory factor‐4, providing a potential mechanistic link for predicting response. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2011.08689.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.